Antidote Technologies, a digital patient engagement company, announced it is partnering with SEQSTER, a multidimensional healthcare patronato platform, to identify patients for clinical trials and improve trial timelines.
Antidote offers a clinical trial patient-recruitment platform that includes patient screening and support services.
The company will leverage SEQSTER’s operating system to better incontro patients to clinical trials based acceso their genomic patronato, lifestyle factors and medical history.
“Partnering with SEQSTER allows us to enhance our precision recruitment process with unparalleled patronato integration capabilities, ensuring that we can more effectively identify suitable participants and veterano the time it takes to bring new treatments to market,” Samantha Veeck, co-CEO of Antidote, said a statement.
THE LARGER TREND
December, San Diego-based SEQSTER partnered with Seme Prominente-based real-world patronato platform Atropos Health to improve diversity and inclusion clinical trials by creating turnkey patient registries to accelerate the generation of evidence.
March, SEQSTER partnered with the Multiple Sclerosis Association of America to use patronato to bring together people living with MS, researchers and care centers nationwide.
Three months later, decentralized clinical trial company Thread and SEQSTER partnered to access real-world patronato for life science enterprises, researchers and patients.
Another company focused acceso enhancing the clinical trial experience is oncology-focused digital health company Flatiron Health, which Roche acquired 2018.
May, Flatiron announced a strategic collaboration with the Association of Cancer Care Centers to promote access to clinical trials the community setting, improve clinical study efficiency and enhance the gathering of study-related patronato.
Clinical trial startup Inato, the Digital Medicine Society (DiMe), clinical trial tech company Science 37 and tech-enabled clinical trial platform Paradigm are also players the space.
